Clinical trials: Erythropoietin
Chronic Renal Failure Requiring Hemodialysis
A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
To determine the long term safety in treatment-emergent adverse events (TEAEs) of SC administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients treated for anemia associated with chronic renal…
- Trial name
- AiME - 04 (NCT01628120)
- Testing
- Epoetin Hospira
- Where
- 115 sites in United States
- Volunteers
- 170 people
- Sponsor
- Pfizer
CABG, Coronary Artery Disease
Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia
This is a phase 2 study that evaluates the effect of intravenous administration of a bolus EPO on the activation of EPOR-signal transduction cascades and myocardial apoptosis during cardiopulmonary bypass surgery.
- Trial name
- DREAM (NCT00524901)
- Testing
- Epoetin alpha, NaCl 0.9%
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Anemia, Renal Failure
Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure
The purpose of this study is to determine if oral Heme Iron Polypeptide is as effective as intravenous (IV) iron sucrose in the treatment of iron-deficiency anemia for patients with chronic kidney disease.
- Trial name
- NCT00318812
- Testing
- Heme Iron Polypeptide (Proferrin), Iron sucrose (Venofer)
- Where
- Canada
- Volunteers
- 55 people
- Sponsor
- Ottawa Hospital Research Institute
Erythropoietin Resistant Anemia (EPO Resistant Anemia)
" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "
The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).
- Trial name
- NCT06983756
- Testing
- Erythropoietin
- Volunteers
- 66 people
- Sponsor
- Fayoum University
Premature Infant
Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis
This study evaluates the effect of repeated low-dose erythropoietin (EPO) treatment on necrotizing enterocolitis (NEC) in very preterm infants. Half of participants will receive EPO, while the other half will receive a placebo.
- Trial name
- NCT03919500
- Testing
- EPO, Normal saline
- Where
- China
- Volunteers
- 1,285 people
- Sponsor
- Zhengzhou University
Traumatic Brain Injury
Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury
Traumatic brain injury is catastrophic event that commonly require treatment in an intensive care unit. Management is mainly supportive aiming at avoiding hypoxia, hypotension, hypoglycaemia and increased intracerebral pressure.
- Trial name
- NCT03061565
- Testing
- erythropoietin
- Where
- Australia
- Volunteers
- 356 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Renal Anemia, Pregnancy
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
The purpose of this study is to estimate the incidence of Pure Red Cell Aplasia (PRCA), neutralising antibodies, lack of efficacy, and thromboembolic events under treatment with Retacrit™ (epoetin zeta) administered…
- Conditions
- Renal Anemia, Pregnancy, Lactation
- Trial name
- PASCO II (NCT01543477)
- Where
- 179 sites in Bulgaria, Croatia and 10 more
- Volunteers
- 4,501 people
- Sponsor
- Pfizer
Chronic Kidney Disease Stages 3-5
Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose
Hypothesis: The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D deficiency in the Chronic Kidney Disease population requiring recombinant human erythropoietin for the treatment of anemia related to kidney…
- Trial name
- EASY (NCT01263028)
- Testing
- Ergocalciferol supplementation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Kaiser Permanente
Infant, Premature, Erythropoietin
High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study
The highest risk for perinatal brain injury occurs among extremely premature infants who weigh less than 1250 grams at birth. Such perinatal brain injury is currently irreversible, associated with neurodevelopmental disability…
- Conditions
- Infant, Premature, Erythropoietin, Brain Injury, Intraventricular Hemorrhage
- Trial name
- NCT00589953
- Testing
- Erythropoietin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Atlantic Health System
Craniosynostosis
Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child
Oral iron is commonly used in conjunction with EPO preoperatively for hemorrhagic surgeries in children and especially in the surgery of craniosynostosis.
- Trial name
- IRON KID (NCT03231085)
- Testing
- Ferrous fumarate or ferrostrane
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Anemia
Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa
The purpose of this trial is to evaluate the physical function outcomes in anemic, critically ill, trauma subjects treated with epoetin alfa (PROCRIT®) compared to placebo.
- Trial name
- NCT00210626
- Testing
- PROCRIT
- Where
- 21 sites in United States
- Volunteers
- 192 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Neoplasms
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
The purpose of this study is to evaluate the cost-effectiveness of epoetin alfa compared with darbepoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer.
- Trial name
- NCT00264108
- Testing
- Darbepoetin alfa, Epoetin alfa
- Where
- 20 sites in Netherlands
- Volunteers
- 492 people
- Sponsor
- Janssen-Cilag B.V.
Anemia, Sickle Cell, Sickle Cell Disease
Hydroxyurea and EPO in Sickle Cell Disease
The proposed study is a Phase 1/2 multi-center study evaluating the safety and efficacy of erythropoietin (EPO) in combination with hydroxyurea in the treatment of chronic anemia in patients with sickle cell disease (SCD).
- Trial name
- ACHiEvE-SCD (NCT05451940)
- Testing
- Hydroxyurea, Epoetin Alfa-BioSimilar
- Where
- 2 sites in United States, Nigeria
- Volunteers
- 17 people
- Sponsor
- Julia Xu
Anemia, Chronic Kidney Disease
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
The purpose of this study was to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneous injections of peginesatide in participants with chronic kidney disease (CKD) not on dialysis who had…
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00228436
- Testing
- peginesatide
- Where
- 13 sites in Poland, United Kingdom
- Volunteers
- 139 people
- Sponsor
- Affymax
Anemia
Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.
This is a phase 4 clinical investigation of the efficacy and safety of Ferrlecit in the maintenance of iron stores and serum hemoglobin concentration in hemodialysis patients receiving Erythropoietin.
- Trial name
- NCT00223938
- Testing
- Oral Iron, sodium ferric gluconate
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- Sanofi
Luspatercept, Epoetin
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT.
- Conditions
- Luspatercept, Epoetin, Poor Erythroid Engraftment, Hematological Malignancies
- Trial name
- NCT07636486
- Testing
- Luspatercept, Epoetin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Anemia, Aortic Stenosis
Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement
The objective of the study is to evaluate the efficacy of Erythropoietin (EPO) (+ iron) in reducing the rate of red blood cell transfusion requirements in patients with aortic stenosis undergoing transcatheter aortic valve…
- Trial name
- EPICURE (NCT02390102)
- Testing
- Erythropoietin
- Where
- Canada
- Volunteers
- 117 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Chronic Kidney Disease, End-stage Renal Disease
MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5
MONITOR-CKD5 is an observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the treatment of renal anaemia with biosimilar epoetin alfa in Stage 5 CKD patients requiring…
- Conditions
- Chronic Kidney Disease, End-stage Renal Disease, Anaemia
- Trial name
- MONITOR-CKD5 (NCT01121237)
- Testing
- Recombinant human erythropoietin alfa (biosimilar)
- Where
- 95 sites in Austria, France and 8 more
- Volunteers
- 2,086 people
- Sponsor
- Sandoz
Anemia, Renal Diseases
PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients
The purpose of this study is to demonstrate that once every-2-weeks and once every-4-weeks treatment with epoetin alfa, a drug that increases red blood cell production, in patients with anemia associated with chronic kidney…
- Trial name
- NCT00440466
- Testing
- epoetin alfa
- Where
- 66 sites in United States
- Volunteers
- 430 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Kidney Disease
Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)
The purpose of this study is to look at subject incidence of adverse events.
- Trial name
- NCT00156962
- Testing
- Epoetin alfa DT, Epoetin alfa RB
- Volunteers
- 850 people
- Sponsor
- Amgen